Navigation Links
Prospective Model Outlined Potential Time and Cost Savings of,Once-Monthly Anemia Treatment

DALLAS, Texas and NUTLEY, N.J., April 23, 2007 /PRNewswire/ -- An activity-based cost analysis demonstrated that if a renal anemia treatment administered once every four weeks replaced thrice weekly administration of epoetin alfa, hemodialysis centers may save an estimated 802 nursing hours and more than $44,000 per year per 100 patients. These data, from a multi-center prospective analysis of anemia management in hemodialysis patients, were presented today during an oral session at the American Nephrology Nurses' Association (ANNA) 38th National Symposium in Dallas, TX.

"Nephrology nurses serve a pivotal role in the care of patients with renal anemia associated with chronic kidney disease," said Sheila Doss, RN, CNN, CCRA, Nursing Director of Research, Satellite Healthcare, Inc. and one of the lead study investigators. "This analysis shows that a once-monthly anemia treatment may significantly reduce the time nurses spend managing the administration of renal anemia medication, allowing us to devote more time to other important aspects of patient care."

About the Analysis

The primary objective of this analysis was to evaluate time and associated in-center supply costs observed while administering epoetin alfa three times a week in patients with renal anemia receiving dialysis, and to model the potential time and cost savings that could be expected if patients switched to a once every four week renal anemia treatment. Researchers concluded that in- center treatment of renal anemia three times a week can be labor-intensive and expensive. The analysis showed that if 100 percent of the patients were given a renal anemia treatment that could be dosed once every four weeks, a greater than 10-fold reduction in time and a similar drop in corresponding costs associated with renal anemia management could result. The researchers noted that time savings are the major contributor to total cost savings. The second component of total cost, non-drug supply costs, are also reduced greater than 10-fold with the model of a once-monthly anemia treatment.

Chronic Kidney Disease and Renal Anemia

According to the National Kidney Foundation, 20 million Americans have chronic kidney disease (CKD) and another 20 million are at increased risk for the condition. CKD is considered a rising global epidemic because it is linked to two of the fastest-growing diseases -- diabetes and hypertension. An often under-diagnosed condition, CKD is called a disease multiplier because many of its risk factors are also complications of the disease itself, creating a relentless spiral in which one condition can lead to the exacerbation of the other and, ultimately, to death. In particular, renal anemia, diabetes and cardiovascular disease frequently play this double role.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. An employer of choice, in 2006, Roche was named one of the Top 20 Employers (Science magazine), ranked the No. 1 Company to Sell For (Selling Power), and one of AARP's Top Companies for Older Workers, and in 2005, Roche was named one of Fortune magazine's Best Companies to Work For in America. For additional information about the U.S. pharmaceuticals business, visit our websites: http://www.rocheusa.com or www.roche.us.

All trademarks used or mentioned in this release are protected by law.

CONTACT: Linda Dyson of Roche , +1-973-562-2231, ; orMonique Kelley of Manning Selvage & Lee, +1-212-468-3015, or cell,+1-609-351-5664, , for Roche linda.dyson@roche.com moniqueellen.kelley@mslpr.com

Web site: http://www.rocheusa.com/http://www.roche.us/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
4. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
5. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
6. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
7. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
8. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
9. RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds Significant Promise for Treating Breast Cancer
10. Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus
11. St. Jude Study Shows Effectiveness of Peramivir in Prevention of Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/19/2017)... Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, ... tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , PhD, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to improve their ... The patient is doing more than filling out a survey; in many cases health ... increasing emphasis in health care and research on the importance of active engagement with ...
(Date:10/13/2017)... ... October 13, 2017 , ... Southern ... and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice Frueh, ... cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU School ...
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
Breaking Medicine News(10 mins):